5th May 2015 06:49
LONDON (Alliance News) - Tissue Regenix Group PLC on Tuesday said it has signed a regional distribution deal in the US for its DermaPure chronic and acute wound treatment device.
Tissue Regenix said it has seen strong commercial demand for the DermaPure device in recent months and has now signed a contract with an unnamed surgical and wound care distribution network. The contract covers two of the twelve states comprising the region covered by the Novitas Medicare reimbursement programme, the company said without naming the states.
The contract is expected to be worth at least USD600,000 over the next twelve months, Tissue Regenix said.
"Our US team has done an outstanding job in achieving commercial traction for DermaPure and signing this regional distribution agreement. This agreement validates the hard work put in since the launch of DermaPure in June 2014, as well as the remarkable clinical results that we are seeing from the product," said Chief Executive Antony Odell.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group